Search the Newsreel

SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells 24,381 Shares

SOPHiA GENETICS (NASDAQ:SOPH) Chairman Jurgi Camblong sold 24,381 shares of the company's stock for $153,356.49, reducing his ownership by 0.69%. This sale, part of a Rule 10b5-1 plan, is one of several recent transactions totaling over 150,000 shares sold since June. The stock currently …

SOPHiA GENETICS (SOPH) Expected to Post Earnings on Tuesday

SOPHiA GENETICS (SOPH) is scheduled to release its Q2 2026 earnings before market open on Tuesday, August 4th. Analysts forecast a loss of $0.21 per share and revenue of $21.72 million for the quarter. The company's stock recently opened at $5.65, and insider sales …

Jurgi Camblong Sells 20,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Sophia Genetics SA (SOPH) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Sophia Genetics SA (SOPH), listing its major shareholders and their proportional holdings, as well as a breakdown of shareholder types. It also provides institutional shareholding data over recent quarters, showing the number of institutions, shares held, and …

Sophia Genetics SA (SOPH) Cash Flow Statement

This article provides the quarterly and annual cash flow statements for Sophia Genetics SA (SOPH), including operating, investing, and financing cash flows, along with related frequently asked questions. It details key financial figures such as net income, capital expenditures, and free cash flow over …

SOPHiA GENETICS SA (NASDAQ:SOPH) Given Average Rating of "Hold" by Brokerages

SOPHiA GENETICS SA (NASDAQ:SOPH) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $9.00. While the company's latest quarterly revenue exceeded estimates, it reported a wider-than-expected loss and is still projected to remain unprofitable this year. Insiders have …

SOPHiA GENETICS (NASDAQ:SOPH) Raised to "Hold" at Zacks Research

Zacks Research upgraded SOPHiA GENETICS (NASDAQ:SOPH) to a "Hold" rating, though the stock has been trading down 1.5% near its 52-week high. Despite some positive sentiment from other analysts regarding its long-term growth and potential profitability by FY2028, the company continues to post weak …

HC Wainwright Estimates SOPHiA GENETICS Q2 Earnings

HC Wainwright has reiterated a "Buy" rating and a $12.00 price target for SOPHiA GENETICS (NASDAQ:SOPH), estimating a Q2 2026 loss of $0.15 per share. The firm projects profitability for SOPHiA GENETICS by FY2028. Despite missing Q2 2026 EPS expectations at $(0.27), the company …

SOPHiA GENETICS (SOPH) affiliate files to sell 37,000 founders shares on NASDAQ

SOPHiA GENETICS (SOPH) has announced that an affiliate, through Morgan Stanley Smith Barney LLC Executive Financial Services, has filed to sell up to 37,000 founders shares on NASDAQ, valued at $234,210.00. The SEC filing also details previous sales by Jurgi Camblong under a Rule …

SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026

SOPHiA GENETICS announced that it will release its financial results for the second quarter of 2026 before U.S. markets open on Tuesday, August 4, 2026. The company will also host a conference call on the same day at 8:00 a.m. EDT / 2:00 p.m. …

SOPHiA GENETICS sets 8 a.m. webcast for Q2 results call

SOPHiA GENETICS (Nasdaq: SOPH) will release its second quarter 2026 financial results before U.S. markets open on August 4, 2026. The company will host a conference call and live webcast at 8:00 a.m. EDT / 2:00 p.m. CET to discuss these results and its …

SOPHiA GENETICS (NASDAQ:SOPH) Hits New 12-Month High - Time to Buy?

SOPH insider (NASDAQ: SOPH) details planned stock and option-related sales

An insider at SOPHiA GENETICS SA (NASDAQ: SOPH) has filed a Form 144 detailing planned sales of common stock. Jurgi Camblong plans to sell 4,581 shares from an option exercise and 19,800 founder shares, with recent sales already conducted under a Rule 10b5-1 trading …

HC Wainwright Initiates Coverage on SOPHiA GENETICS (NASDAQ:SOPH)

HC Wainwright has initiated coverage on SOPHiA GENETICS (NASDAQ:SOPH) with a "buy" rating and a $12 price target, indicating a potential 104% upside. This positive outlook, shared by BTIG Research, contrasts with a "sell" rating from Weiss Ratings, leading to an overall "Moderate Buy" …

H.C. Wainwright initiates Sophia Genetics stock with buy rating By Investing.com

H.C. Wainwright has initiated coverage on Sophia Genetics SA (NASDAQ: SOPH) with a Buy rating and a $12.00 price target, suggesting over 100% upside. The company operates an AI-driven genomics platform used by hospitals and labs globally, generating recurring revenue. Sophia Genetics recently closed …

SOPHiA GENETICS prices $50M public offering at $4.75 per share

SOPHiA GENETICS has priced a public offering of 10,526,316 shares at $4.75 per share. The offering is expected to raise approximately $50 million in gross proceeds. This financial move aims to secure capital for the company.

SOPHiA GENETICS SA 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:SOPH) 2026-05-07

ASX Energy Stock Synertec Taps Global Power Giant for Growth

SOPHiA GENETICS Reports First Quarter 2026 Results

BTIG Raises its Price Target on SOPHiA GENETICS (SOPH) to $8

How The SOPHiA GENETICS (SOPH) Narrative Is Shifting With Recalibrated Growth And Valuation Assumptions

Synertec Corporation Limited's (ASX:SOP) Shares Leap 30% Yet They're Still Not Telling The Full Story

Sopra Steria Group: Prévisions et Estimations des Analystes | SOP

SOPHiA GENETICS (SOPH) Earnings Date and Reports 2026

Technical Analysis of Synertec Corporation Limited (ASX:SOP)

Synertec Corporation Limited (SOP.AX) valuation measures and financial statistics